← Back to Search

Serotonin Modulator and Stimulator

Vortioxetine for Social Anxiety Disorder

Phase 4
Waitlist Available
Led By Michael R Liebowitz, M.D.
Research Sponsored by The Medical Research Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This placebo-controlled study is designed to determine the efficacy, safety, and tolerability of vortioxetine in the treatment of adults with Major Depressive Disorder (MDD) that is comorbid with Social Anxiety Disorder (SAD). Half of the subjects will be randomized to receive vortioxetine and the other half will receive placebo.

Eligible Conditions
  • Social Anxiety Disorder
  • Depression

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical Global Impression of Improvement (CGI-I) Responder Rate
Secondary outcome measures
Change in total Liebowitz Social Anxiety Scale (LSAS) score
Change in total Montgomery Asberg Depression Rating Scale (MADRS) score

Side effects data

From 2019 Phase 4 trial • 1106 Patients • NCT02371980
26%
Nausea
8%
Headache
5%
Nasopharyngitis
5%
Dry mouth
100%
80%
60%
40%
20%
0%
Study treatment Arm
Open-label: Vortioxetine 10 mg
Double-blind: Placebo
Double-blind: Vortioxetine 5 mg
Double-blind: Vortioxetine 10 mg
Double-blind: Vortioxetine 20 mg

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: VortioxetineExperimental Treatment1 Intervention
Vortioxetine 10 to 20 mg PO QD for 12 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Placebo PO QD for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vortioxetine
FDA approved

Find a Location

Who is running the clinical trial?

The Medical Research NetworkLead Sponsor
5 Previous Clinical Trials
270 Total Patients Enrolled
Michael R Liebowitz, M.D.Principal InvestigatorThe Medical Research Network, LLC

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder
2014. "Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02294305.
All > Anxiety Disorder > Social Anxiety
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top